Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Puntos clave

• This research aims to assess the effectiveness of cetuximab alone and in combination with irinotecan for treating irinotecan-refractory metastatic colorectal cancer.
• Evaluated cetuximab monotherapy and combination with irinotecan in a clinical setting.
• Focused on patients with irinotecan-refractory metastatic colorectal cancer.
• Cetuximab showed significant clinical activity as monotherapy.
• Combination therapy with irinotecan resulted in enhanced effectiveness compared to monotherapy.